Efficacy and safety of givosiran for acute hepatic porphyria: Final results of the randomized phase III ENVISION trial
{{output}}
Background & aims: Acute hepatic porphyria (AHP) is caused by defects in hepatic heme biosynthesis, leading to disabling acute neurovisceral attacks and chronic symptoms. In ENVISION (NCT03338816), givosiran treatment for 6 month... ...
